SECsense Logo

Bionano Genomics 8-K Report: Key Financial Updates as of February 4, 2025

$BNGO
Form 8-K
Filed on: 2025-02-10
Source
Bionano Genomics 8-K Report: Key Financial Updates as of February 4, 2025

Based on the provided XML section of a financial report from Bionano Genomics, Inc., here are the key takeaways:

  1. Entity Identification:
  • Company Name: Bionano Genomics, Inc.
  • CIK Number: 0001411690
  • SEC File Number: 001-38613
  • EIN: 26-1756290
  1. Report Type:
  • The filing type is an 8-K, which typically reports significant events that shareholders should know about.
  1. Filing Date:
  • The report is dated February 4, 2025.
  1. Location:
  • The company is located at 9540 Towne Centre Drive, Suite 100, San Diego, CA 92121.
  1. Contact Information:
  • Phone Number: 858-888-7600
  1. Stock Information:
  • Common Stock: The par value is $0.0001 per share.
  • Ticker Symbol for Common Stock: BNGO (traded on NASDAQ).
  • Warrants to Purchase Common Stock: Ticker Symbol for warrants is BNGOW (also traded on NASDAQ).
  1. Context Period:
  • The financial data presented covers a specific date, February 4, 2025, indicating that the report may provide insights or updates relevant to that date.
  1. Stock Classifications:
  • The report mentions "Warrants to Purchase Common Stock" and "Common Stock," suggesting that both types of equity instruments are relevant to the company's financial reporting.

Insights:

  • The filing indicates that Bionano Genomics is actively managing its equity instruments, which may be pertinent for investors looking at potential investment opportunities or assessing the company's capital structure.
  • The use of warrants indicates a strategy that might involve raising additional capital or incentivizing investors and stakeholders.
  • Being listed on NASDAQ suggests a level of regulatory compliance and a certain stature in the market, which could be a positive indicator for investors.